Recent News
Persistence of education and monitoring is crucial to optimal gout management
It is important that the misconceptions and myths held by the patient are discussed and dispelled and, most importantly, establish a clear understanding of “the plan” and the reason for initiating urate-lowering therapy (ULT).
Read Article
QD Clinic: Gout: Is it the Journey or the Destination?
Dr. Arthur Kavanaugh discusses a gout patient whose frequent flares improved after lifestyle changes, despite medication not being enough on its own.
https://t.co/frf4O87L0I https://t.co/cjtiYY9Ayt
Dr. John Cush @RheumNow ( View Tweet)
Predicting and Managing Gout Flares in Hospitalized Patients
Dr. Kanon Jatuworapruk, Bangkok, discusses predicting and managing gout flares in hospitalized patients as part of RheumNow's "Gout: More than Flares" campaign in July 2026.
https://t.co/wrLbjsayrI https://t.co/eWmRqPNWsJ
Dr. John Cush @RheumNow ( View Tweet)
51 yoM w/ 2 yrs of FUO, unintentional 32-kg wt loss, LN, diffuse myalgias, but no GI Sxs or arthralgia. Neg MRIs, CT, PET scan, EGD, colonoscopy. Abnl labs: CRP 173 mg/L, ESR 46, anemia & ^ WBC. Cell-free DNA next-generation sequencing dx Tropheryma whipplei, & Whipple disease https://t.co/nJLa4l7Ers
Dr. John Cush @RheumNow ( View Tweet)
Genetic study of 16 pts w/ Allopurinol-induced severe cutaneous adverse Rxn (SJS/TEN) shows 2 class I alleles to be associated: HLA-B*58:01 (OR, 28.0 [95% CI, 8.6-100.6]) and HLA-A*34:02 (OR, 20.6 [95% CI, 3.3-131.1]). Both explain 80% risk in US pts https://t.co/OxDXuWCbup https://t.co/oky61JImQV
Dr. John Cush @RheumNow ( View Tweet)
Psoriatic Arthritis: EULAR 2026 Recap
https://t.co/tBMu4CEn0o https://t.co/iztShOHxOf
Dr. John Cush @RheumNow ( View Tweet)
Seronegative RA Disease Activity (7.17.2026)
Dr. Jack Cush reviews the news, journal articles and Gout features from this past week on RheumNow and check your knowledge in this week's RheumIQ quiz!
https://t.co/e0u9qwtHVi https://t.co/oav00L7Lzw
Dr. John Cush @RheumNow ( View Tweet)
Expert Perspective on Calcium Pyrophosphate Deposition Disease
A recent perspective by Tedeschi tackles many unresolved issues around CPPD diagnosis, classification, and management, including the lack of clinical trials or FDA approved treatments.
Read Article
Pragmatism in Gout: How therapeutic choices can have multiple benefits
William James famously wrote in Pragmatism, “There can be no difference anywhere that doesn’t make a difference elsewhere.” Gout treatment offers a striking medical example of that idea. Drugs prescribed to calm flares or lower uric acid are designed with one primary goal in mind, yet many also produce meaningful effects beyond the joints.
Read Article
2 Still's dz cohorts (96 Shanghai, 28 Erlangen0 compared response to biolgics vs DMARDs (MTX, CNI,JAKi). in 124 AOSD pts, biologic had more sustained event-free remission and event-free state (P 0.0065, P 0.0096) & more steroid D/C vs MTX/CNI (p < 0.05). https://t.co/lJaI9nhPYr
Dr. John Cush @RheumNow ( View Tweet)
ACR: Medicare Cuts for Physicians Highlight Need for Reform
The ACR was disappointed that the proposed MPFS from the CMS once again included a serious cut to the conversion factor. The -1.68% cut would lower reimbursement to physicians providing care to Medicare beneficiaries https://t.co/PmAmFPnw6R
Dr. John Cush @RheumNow ( View Tweet)
The Marriage between Gout and the Kidney
While the link between uric acid and gout was first described by Alfred Baring Garrod in the 1800s, the proof that uric acid might actually be the cause had to await the self-experimentation of two rheumatologists from the University of https://t.co/AWZbjaUtdu
Dr. John Cush @RheumNow ( View Tweet)
From 2015-2024, 148 inflam arthritis pts (43 SpA, 35 PsA, 50 RA) w/ a prior cancer were followed 58.1 mos. 24 (19%) had CA recurrence/progression. Post-CA exposure to b/ts-DMARDs did not incr. recurrence risk after adjusting for age & comorbidity burden. https://t.co/MHKIqwyjNN https://t.co/uhOdq1cCPW
Dr. John Cush @RheumNow ( View Tweet)
RHEUM SURVEY Q: Which gout drug has the greatest toxicity risk? Answer here>> https://t.co/EQrEjD9237
Dr. John Cush @RheumNow ( View Tweet)
SGLT2i use in gout reduces use of gout meds. Study of 26,739 gout pts w/ NIDDM (mean 66 yrs), 67% w/ polypharmacy. SGLT2i (vs DPP-4i) user had less Allopurinol starts (HR 0.62;0.52–0.73), also lower use of steroids (,78), NSAID (.85), colchicine (.87) & diuretics (.87) https://t.co/1dW27YzSvg
Dr. John Cush @RheumNow ( View Tweet)
GI dz & malnutrition in scleroderma (SSc) is common, assessed by BMI. Among 450 SSc (F/U 5.3 yrs), lower BMI were significantly assoc w/ pseudoobstruction, smaller oral aperture, higher Medsger vascular severity scores. Defines those at risk https://t.co/w45OhUOUTh https://t.co/hWuIaS6OUe
Dr. John Cush @RheumNow ( View Tweet)
Metanalysis of 51 studies shows vaccination is suboptimal in Rheum. Influenza Vax rates: RA 50%, SLE 42%, AS 43% & Psa 53%. Pneumococcal vaccinations even lower: 37%, 30%, 39% and 41%. More by with age & comorbidites and by rheumatologists (vs PCPs) https://t.co/3DborC9BLW https://t.co/MPDeJUH0HI
Dr. John Cush @RheumNow ( View Tweet)
Gout in Minority Populations
Recent research has revealed substantial racial and ethnic disparities in both who develops gout and the care patients receive. These differences reflect not only genetic susceptibility but also the substantial influence of social determinants of https://t.co/SKEsQVZPw6
Dr. John Cush @RheumNow ( View Tweet)
Low dose ASA (81mg or 325mg) increase gout attacks by 81% (RR 1.81). Effect nullified by allopurinol use.
For more gout content, follow our Gout: More than Flares campaign at https://t.co/lQoiFjubZJ, https://t.co/sSm4s3vUtE
Dr. John Cush @RheumNow ( View Tweet)
Video
From the Blog
At first, it seemed similar to many other such sessions – a circle of folding chairs, a group of colleagues whose visages exuded understanding and acceptance – but this was special. I started the meeting…. “Hi, my name is Artie.”
Read Post
Podcasts
Upgrading & Maximizing the Classics (Colchicine, Allopurinol, etc.)
Seronegative RA Disease Activity (7.17.202)-
What Lies Beneath - Uric Acid Deposition & Imaging
Gout QD clinics - lessons from the Clinic QD307-QD311
Therapeutic Updates
Fundamentals of CAR T Cell Therapy and Its Investigational Use in Autoimmune Diseases
Sponsored By Bristol Myers Squibb
Learn more about the fundamentals of CAR T-cell therapy and its investigational use in autoimmune disease
Read Post
Watch our 'Systemic Burden of Gout' series as part of this month's Gout More than Flares campaign. Check out our videos including: Gout & CVD, Gout & Obesity, Outcomes of Tophaceous Gout and more.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
Real-World Joint Outcomes With an IL-23i vs TNFi or IL-17i in PsA
Daily Gem
Rheumatoid arthritis is found in 2-3.8% of gout patients.
--